Author

Megan M. Cleary

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Charles Keller· 1 shared Douglas S. Hawkins· 1 shared

Activity by Year

2019-2019 · peak 1/yr

Co-Author Collaboration Network

2 top collaborators · 1 mutual co-author link

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Charles Keller

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintApr 29, 2019

Efficacy of the MEK1/2 inhibitor trametinib in combination with clinically-investigated γ-secretase inhibitors in rhabdomyosarcoma

Megan M. Cleary, Douglas S. Hawkins, Charles Keller

This study tests the efficacy of trametinib and gamma-secretase inhibitors in RMS cell lines, finding no significant effect on cell viability when combined.

DOI 10.1101/622522

humanbulk RNA-seq

𝕏 PostBluesky